2 weeks on tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Week 2 on my Tirzepatide

Although findings from clinical studies are promising, there are concerns that long-term exposure of GLP-1 RAs at supratherapeutic or maximum approved maintenance doses may impair muscle cell differentiation and potentially contribute to the development of sarcopenia, despite their potential to improve muscle metabolism and quality [83, 88]

While US obesity rates have been on the rise for years, 2023 marked the first dip in over a decade

The bodys response to these adjustments can sometimes manifest as fatigue, anxiety, or mild discomfort

Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets

Sorensen MD, Kahn AJ, Reiner AP, et al